The typical formulation you will encounter is tirzepatide/cyanocobalamin at a concentration of 2.5mg/1mg per 0.5mL, though concentrations vary widely between pharmacies and prescriptions
In clinical trials for type 2 diabetes (SURPASS), nausea was reported by approximately 12-29% of patients receiving tirzepatide, depending on the dose, compared to 6-8% receiving placebo
Bydureon (exenatide) : Bydureon is unique for its extended-release formulation, requiring only once-weekly injections
To help with the backlog, the FDA has approved the compounding of these substances
Physicians should be aware that allergic symptoms may reappear when symptomatic therapy has been discontinued
Its crucial to discuss all medical conditions and current medications with a healthcare professional to ensure tirzepatide is safe and appropriate for your situation